ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
Ulrich Keilholz(German Cancer Research Center), Olivier Michielin(SIB Swiss Institute of Bioinformatics), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), P.A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roger Olofsson Bagge(Sahlgrenska University Hospital), John B.A.G. Haanen(Leiden University Medical Center), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Matthias Gückenberger(University Hospital of Zurich), Célèste Lebbé(Inserm), Marco Donia(University of Copenhagen), Caroline Gaudy‐Marqueste(Aix-Marseille Université), Iwona Ługowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Reinhard Dummer(University Hospital of Zurich), Christoph Höeller(Medical University of Vienna), Jean‐Jacques Grob(Aix-Marseille Université), Vernon K. Sondak(Advanced Dermatology), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Paul Lorigan(Manchester Academic Health Science Centre), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Alexander C. J. van Akkooi(The University of Sydney), Susana Puig(Instituto de Salud Carlos III), Mark B. Faries(Angeles Clinic and Research Institute), Bart Neyns(Universitair Ziekenhuis Brussel), Paul Nathan(Mount Vernon Hospital), Christian U. Blank(The Netherlands Cancer Institute), Helen Gogas(National and Kapodistrian University of Athens), Caroline Robert(Institut Gustave Roussy), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Andrew Hayes(Royal Marsden NHS Foundation Trust), Bastian Schilling(Goethe University Frankfurt)
Cited by 232
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k